The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BOLT | -53.31% | -99.5% | -65.3% | -99% |
| S&P | +18.81% | +68.58% | +11.01% | +72% |
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.50M | 0.0% |
| Gross Profit | $2.25M | 627.0% |
| Gross Margin | 89.80% | 0.0% |
| Market Cap | $10.50M | -48.8% |
| Market Cap / Employee | $456.33K | 0.0% |
| Employees | 23 | -55.8% |
| Net Income | -$6,631.00K | 58.4% |
| EBITDA | -$5,350.00K | 64.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.90M | 49.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $20.13M | -12.3% |
| Short Term Debt | $2.83M | 25.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -41.20% | 7.5% |
| Return On Invested Capital | -77.57% | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7,156.00K | 50.4% |
| Operating Free Cash Flow | -$7,156.00K | 50.4% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.33 | 0.24 | 0.26 | 0.33 | -8.84% |
| Price to Sales | 4.22 | 2.66 | 1.97 | 1.23 | -53.93% |
| Price to Tangible Book Value | 5.36 | 0.24 | 0.26 | 0.33 | -94.25% |
| Enterprise Value to EBITDA | -0.04 | 0.03 | -0.15 | -0.88 | -655.01% |
| Return on Equity | -83.9% | -81.3% | -82.0% | -79.7% | 7.36% |
| Total Debt | $24.71M | $24.18M | $23.59M | $22.96M | -8.93% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
